检索历史 清除

目的 探讨胸腺肽α1 联合培美曲塞治疗局部晚期非小细胞肺癌的临床治疗效果.方法 选取2012年3月至2017年3月孝义市人民医院呼吸科收治的63例局部晚期非小细胞肺癌患者,采用简单随机化法随机分为单药治疗组(n=31)与联合治疗组(n=32).单药治疗组运用胸腺肽α1进行治疗,联合治疗组运用胸腺肽α1联合培美曲塞进行治疗.比较两组患者的近期治疗效果、急性不良反应发生率、治疗后外周血T细胞亚群水平、治疗后血小板数、血红蛋白量、白细胞数的变化.结果 联合治疗组患者有效率(93.7% )高于单药治疗组(74.2% ),差异有统计学意义(P<0.05).联合治疗组患者的急性不良反应发生率(9.3% )显著低于单药治疗组(38.7% ),差异有统计学意义(P<0.05).联合治疗组患者的CD4 +[(50.5 ± 1.7)% ]、CD8 +[(18.4 ± 0.8)% ]、CD4 +/CD8 +[(2.5 ± 0.7)%]均高于单药治疗组[(44.5 ± 1.8)%、(16.2 ± 1.2)%、(2.3 ± 0.5)% ],差异有统计学意义(P<0.05).联合治疗组患者的血小板数[(159.5 ±51.4)×109个/L]、血红蛋白量[(107.6 ± 12.8) g/L]、白细胞数[(3.6 ± 2.2) ×109个/L]的变化均高于单药治疗组[(148.7 ±46.6) ×109个/L、(99.3 ±12.5)g/L、(3.1 ±1.6) ×109个/L],差异有统计学意义(P<0.05).结论 局部晚期非小细胞肺癌的治疗过程中,胸腺肽α1联合培美曲塞的治疗效果更好,降低患者不良反应的发生率,提高患者的生活质量和预后,值得在临床上进一步推广应用.

Objective To investigate the clinical efficacy of thymosin α1 combined with peme-trexed in the treatment of locally advanced non-small cell lung cancer (NCLC). Methods A retrospective study was performed on 63 cases of patients with locally advanced NCLC who were admitted from March 2012 to March 2017.Patients were randomly divided into the monotherapy group (n=31)and the combined treatment group (n=32).The monotherapy group of patients were treated with thymosin α1,while the com-bined treatment group of patients were treated with thymosin α1 combined with pemetrexed.The short-term therapeutic effect,the incidence of acute adverse reactions,the level of peripheral blood T lymphocyte sub-sets,the number of platelets,hemoglobin and white blood cells after treatment were compared between the two groups. Results The effective rate of patients in the combined treatment group (93.7% ) was higher than that in the monotherapy group (74.2% ),and the difference was statistically significant (P<0.05). The incidence of acute adverse reactions (9.3% ) in the combined treatment group was significantly lower than that in the monotherapy group (38.7% ,P<0.05).Combined treatment group of patients with CD4 +[(50.5 ± 1.7)% ],CD8 +[(18.4 ± 0.8)% ],CD4 +/CD8 +[(2.5 ± 0.7)% ] were higher than those in the monotherapy group [(44.5 ± 1.8)% ,(16.2 ± 1.2)% ,(2.3 ± 0.5)% ],and the difference was statis-tically significant (P<0.05).The changes in platelet count [(159.5 ± 51.4) ×109/L],hemoglobin level [(107.6 ± 12.8)g/L] and leukocyte count [(3.6 ± 2.2) ×109/L] in the combined treatment group were all higher than those in the monotherapy group [(148.7 ± 46.6) ×109/L,(99.3 ± 12.5) g/L,(3.1 ± 1.6) ×109/L],(P<0.05). Conclusion Thymosin α1 combined with pemetrexed is more effective in the treatment of locally advanced non-small cell lung cancer, which can reduce the incidence of adverse reactions,improve the quality of life and prognosis of patients,and is worthy of further clinical application.